Core Funding Programs

The ADDF provides funding to academic centers and biotechs from around the world that are advancing therapeutic and biomarker development for Alzheimer's and related dementias. We have dedicated our funding to several key areas:

  • Translational research to develop new drugs and build preclinical evidence
  • IND-enabling studies and early-stage clinical trials for novel and repurposed drugs
  • Development and validation of plasma, CSF, neuroimaging and digital biomarkers
  • Epidemiological studies and comparative effectiveness research

Applications are reviewed throughout the year through our core programs.


NOTE: Due to the COVID-19 pandemic, we understand there may be delays in submitting applications. We will consider an extension if delays are anticipated. Please email the scientific contact listed on the relevant RFP to discuss further.

Upcoming 2021 deadlines
Must be received by 5:00 pm ET on the deadline date. (2pm Pacific Time)

Letter of Intent: February 5, 2021       Invited Full Proposal: April 16, 2021

Letter of Intent: May 28, 2021             Invited Full Proposal: July 30, 2021

Letter of Intent: October 1, 2021         Invited Full Proposal: December 3, 2021

Please see the links below for eligibility and funding opportunity details

Drug Development RFP
Program to Accelerate Clinical Trials (PACT) RFP
Neuroimaging and CSF Biomarker Development RFP
Prevention Pipeline RFP

ADDF/NIH Funding and SBIR/STTR Bridge Funding Opportunities







Upcoming Deadlines